AbbVie stock (US00287Y1091): investors eye Skyrizi and Rinvoq momentum after latest quarterly update

AbbVie has recently reported new quarterly results that underscore the growing importance of immunology drugs Skyrizi and Rinvoq in offsetting the continued sales decline of former blockbuster Humira, according to AbbVie’s quarterly earnings release published in late April 2026 and related coverage from major financial media on the same date, including Reuters as of 04/26/2026 and AbbVie’s investor relations materials as of 04/26/2026.

As of: 05/20/2026

By the editorial team – specialized in equity coverage.

AbbVie Inc.: core business model

AbbVie is a large US-based biopharmaceutical company that focuses on the research, development, and commercialization of branded prescription medicines. The business model combines a portfolio of established therapies with newer specialty drugs that target chronic and often difficult-to-treat conditions, according to AbbVie’s corporate profile and latest Form 10-K filed in February 2026 with the US Securities and Exchange Commission, as referenced by SEC as of 02/16/2026.

The company historically derived a large share of revenue from Humira, an immunology drug used in conditions such as rheumatoid arthritis and Crohn’s disease. As biosimilar competition has increased in the United States and Europe, AbbVie has been repositioning its portfolio toward newer agents, notably Skyrizi and Rinvoq, which target psoriasis, psoriatic arthritis, ulcerative colitis, and related immune-mediated diseases, as explained in AbbVie’s 2025 annual report and reiterated in its April 2026 earnings materials, according to AbbVie investor relations as of 04/26/2026.

AbbVie also operates significant franchises in oncology, aesthetics, and neuroscience. The oncology portfolio includes therapies for blood cancers, while aesthetics features products such as Botox Cosmetic and dermal fillers. Neuroscience covers treatments for conditions including migraine and certain psychiatric disorders. This diversification aims to reduce reliance on any single product and provides exposure to multiple therapeutic growth drivers across the US and global pharmaceutical markets.

Main revenue and product drivers for AbbVie Inc.

In its latest quarterly update for the first quarter of 2026, AbbVie reported that total revenue reflected declining Humira sales, particularly in the US, offset by strong growth of Skyrizi and Rinvoq as well as solid contributions from aesthetics and neuroscience. The company highlighted double-digit year-over-year growth for these newer immunology agents, while acknowledging that Humira erosion remained a headwind for overall top-line expansion, according to the first-quarter 2026 earnings press release and slide deck published on April 26, 2026, referenced by AbbVie earnings materials as of 04/26/2026.

Skyrizi is positioned as a treatment for moderate to severe plaque psoriasis and other inflammatory conditions, while Rinvoq is used in rheumatoid arthritis and a range of additional autoimmune indications. Regulators in the United States, including the Food and Drug Administration, have approved expanded labels for these drugs over the past several years, enabling AbbVie to increase addressable patient populations and drive higher utilization in both US and international markets, as reflected in various FDA approvals and company communications through 2024 and 2025, according to FDA announcements as of 11/15/2025.

Beyond immunology, the aesthetics segment, which includes Botox and other products obtained through the acquisition of Allergan in 2020, remains an important contributor to AbbVie’s earnings. Demand for aesthetic procedures in the US has been supported by consumer spending and a growing range of minimally invasive treatments offered by medical practices. AbbVie’s neuroscience and oncology therapies provide further diversification, though these franchises are at different stages of their product life cycles and face competition from other major pharmaceutical companies in the US and abroad.

Industry trends and competitive position

AbbVie operates in a competitive global biopharmaceutical industry where large companies and specialized biotechnology firms invest heavily in research and development to bring new therapies to market. The sector is characterized by long development timelines, high regulatory requirements, and patent-driven revenue cycles. As patents expire, branded drugs often face generic or biosimilar competition, which can pressure pricing and volumes in key markets such as the United States, according to sector overviews from S&P Global and other research providers published during 2025, including S&P Global Market Intelligence as of 09/30/2025.

Within immunology, AbbVie competes with several major pharmaceutical and biotechnology companies that offer alternative treatments for autoimmune diseases. The competitive landscape includes both injectable biologics and oral small-molecule drugs, some of which are priced aggressively or target similar mechanisms of action. AbbVie’s strategy has emphasized broad clinical programs for Skyrizi and Rinvoq to differentiate on efficacy and safety data across multiple indications, as described in the company’s pipeline and portfolio updates throughout 2025 and in early 2026, according to AbbVie presentations as of 01/10/2026.

The company’s acquisition history, including the Allergan transaction, has expanded AbbVie’s presence in aesthetics and neuroscience, giving it scale and brand recognition in areas such as Botox Cosmetic and migraine treatments. This portfolio breadth helps position AbbVie among the world’s largest biopharmaceutical groups by revenue, and its NYSE listing and inclusion in major US indexes make the stock widely followed by institutional and retail investors in the United States.

Why AbbVie Inc. matters for US investors

For US-based investors, AbbVie represents exposure to a large-cap pharmaceutical company with significant domestic revenue and a broad presence in major therapeutic categories. The company generates a substantial portion of its sales in the United States and is influenced by US healthcare policy, reimbursement frameworks, and competitive dynamics within large insurance and pharmacy benefit manager networks. Its shares trade on the New York Stock Exchange under the ticker ABBV, a venue that is central to US equity markets and widely accessible to retail brokerage platforms, according to listing information from the NYSE and market data providers as of early 2026, referenced by NYSE as of 03/01/2026.

AbbVie’s dividend policy and history of returning capital to shareholders through cash distributions and share repurchases have also made the stock a focus for income-oriented investors. While dividend decisions are subject to board approval and business performance, AbbVie has paid regular quarterly dividends in recent years and has communicated capital allocation priorities that include supporting research and development, servicing debt, and distributing cash to shareholders, according to company statements and dividend announcements published throughout 2025 and in early 2026, including AbbVie news releases as of 02/15/2026.

At the same time, regulatory initiatives aimed at controlling drug prices in the United States, such as elements of the Inflation Reduction Act and discussions around Medicare drug price negotiations, introduce policy-related uncertainties for AbbVie and its peers. Outcomes in this area can influence revenue trajectories for certain medicines and may shape how the company prioritizes its US product portfolio and pricing strategies over the medium term, as discussed in policy analyses and company commentary during recent earnings calls in 2024 and 2025.

Conclusion

The latest quarterly results highlight AbbVie’s ongoing transition from a Humira-centric revenue base toward a more diversified portfolio anchored by Skyrizi, Rinvoq, and key aesthetics and neuroscience products. While the erosion of Humira sales remains a notable headwind, momentum in newer immunology drugs and contributions from acquired franchises demonstrate the company’s efforts to reshape its earnings profile. For US investors, AbbVie offers exposure to the domestic and global pharmaceutical industry with a focus on specialty medicines and a history of dividend payments, but the stock’s future trajectory will depend on clinical outcomes, regulatory developments, competitive pressures, and management’s execution on pipeline and portfolio strategies in the coming years.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.